Founder led companies can offer something many investors value in markets shaped by inflation questions, interest rate uncertainty and uneven growth data. These leaders often have more of their own wealth tied to the business, which can create strong focus on capital allocation, resilience and long term value. The Founder-Led Companies screener is built to help you find these committed operators without having to sift through every stock yourself. In this article you will see three of the standout stocks that currently pass the screener and why each one may deserve a closer look in your own research process.

Coinbase Global (COIN)

Overview: Coinbase Global runs a large crypto asset platform that lets consumers buy, sell and hold digital assets, institutions access deep trading liquidity, and developers build on blockchain infrastructure. Founded in 2012 and based in New York, it aims to be a primary entry point into the broader crypto and onchain economy.

Market Cap: US$43.1b

Investors looking at founder led companies may find Coinbase Global interesting because it sits at the crossroads of crypto trading, tokenization and blockchain based payments while pushing to reduce its reliance on volatile spot volumes. Partnerships with large financial institutions and the build out of products like Base and USDC related services are aimed at growing higher margin, recurring revenue streams, even as recent results highlight pressure from weaker trading activity and higher compliance and cybersecurity costs. The company remains unprofitable and carries funding and regulatory risks, yet its role in linking traditional finance to digital assets means you could be missing an important part of the onchain story if you overlook it.

Coinbase Global sits at the center of crypto trading, tokenization and onchain payments, yet its push into Base, USDC services and institutional partnerships is easy to underestimate. Get the fuller picture with the analysis report for Coinbase Global

Corcept Therapeutics (CORT)

Overview: Corcept Therapeutics is a biopharmaceutical company that develops drugs targeting the hormone cortisol to treat severe endocrine, cancer, metabolic and neurologic conditions. Its portfolio includes the approved Cushing’s syndrome drug Korlym and newer selective cortisol modulators such as relacorilant, miricorilant, nenocorilant and dazucorilant, with uses ranging from metabolic liver disease to Lou Gehrig’s disease.

Market Cap: US$12.8b

Corcept Therapeutics may appeal to investors seeking exposure to a focused cortisol science story that is already generating revenue while adding new growth engines. The company is using its Cushing’s franchise and newly approved ovarian cancer drug Lifyorli to fund a wider pipeline, including relacorilant for both Cushing’s syndrome and platinum resistant ovarian cancer. Recent trial and label developments have led the company to issue 2026 revenue guidance in the US$1.1b to US$1.2b range. At the same time, heavy dependence on Korlym pricing, active litigation, high use of external funding and a share price that screens as expensive versus intrinsic value estimates mean that execution and regulatory outcomes may be particularly important for Corcept.

Corcept Therapeutics sits at the crossroads of cortisol science and revenue guidance that already stretches to US$1.1b to US$1.2b for 2026, yet many investors still treat it cautiously. See how the current pipeline, litigation overhang and valuation premium line up in the 1 key reward and 1 important warning sign

AppLovin (APP)

Overview: AppLovin runs an AI powered advertising platform that helps app developers, e commerce brands and other businesses find and monetize users across mobile apps and connected TV. Through products like Axon Ads Manager, MAX bidding, Adjust analytics and Wurl streaming distribution, AppLovin connects advertisers with large audiences and gives publishers tools to manage and grow their ad revenue.

Operations: AppLovin currently generates about US$6.2b in revenue, all from its Advertising segment, with sales roughly split between the United States at US$3.1b and the rest of the world at US$3.0b.

Market Cap: US$135.7b

AppLovin may be of interest if you are looking at a founder led AI story that already has scale and profits. The core Axon ad engine, MAX and Adjust contribute to earnings that analysts describe as high quality, with ROE above 100% and strong net margins. A shift from gaming into e commerce and other categories also broadens the opportunity. At the same time, heavy reliance on mobile platforms, tight data privacy rules and strong competition from larger ad and software companies could affect monetization and margins if conditions change. The recent share price pullback and insider selling highlight the importance of assessing whether the current valuation aligns with the company’s growth, buybacks and cash generation.

AppLovin’s scale, profits and founder leadership sit at the heart of this AI ad story, yet the real twist may be what current expectations are missing. See how the market’s growth hopes stack up in the analyst forecasts for AppLovin

The three founder led stocks in this article are only a starting point, since the full screener has identified 351 more companies with equally compelling founder stories and aligned incentives. If you want to unlock deeper conviction and identify the leaders whose catalysts match your own thesis, run the Founder-Led Companies screener.

Take Control of Your Investment Journey

If Corcept Therapeutics or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly

Some of the most interesting stories start moving quietly, then break out while most investors are still watching yesterday’s winners. Scan these fresh ideas before momentum is caught and consider them while they are still emerging.

• Target dependable income streams while rates shift by screening companies in the 9 dividend fortresses that focus on durable payouts many investors only notice after yields start dropping.
• Spot early AI activity before it becomes widely followed by running the 70 profitable AI stocks that aren't just burning cash where businesses already turn machine learning into cash flow rather than just headlines.
• Explore opportunities connected to the power grid upgrade cycle with the 35 power grid technology and infrastructure stocks so you can review infrastructure stocks while they are still under the radar for now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.